Organovo Holdings, Inc. is a biotechnology company that focuses on building high fidelity, three-dimensional (3D) tissues that recapitulate various aspects of human disease. The Company uses these models to identify gene targets responsible for driving the disease and intends to initiate drug discovery programs around these validated targets. It is initially focusing on the intestine and has ongoing 3D tissue development efforts in ulcerative colitis (UC) and Crohns disease (CD). The Company uses its technology to build functional 3D human tissues that mimic various aspects of native human tissue composition, architecture, function, and disease. Its NovoGen Bioprinters are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells. Its NovoGen Bioprinters can also dispense pure hydrogel formulations, provided the physical properties of the hydrogel are compatible with the dispensing parameters. Its 3D human tissue platform is multifaceted.

• Revenue in USD (TTM)242.00k
• Net income in USD-19.09m
• Incorporated2012
• Employees15.00

• Location
  Organovo Holdings IncSuite 110, 6275 Nancy Ridge DriveSAN DIEGO 92121United StatesUSA
• Phone+1 (858) 550-9994
• Fax+1 (302) 636-5454
• Websitehttps://organovo.com/